120 related articles for article (PubMed ID: 18040121)
21. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3.
Brandolese R; Scordo MG; Spina E; Gusella M; Padrini R
Clin Pharmacol Ther; 2001 Oct; 70(4):391-4. PubMed ID: 11673755
[TBL] [Abstract][Full Text] [Related]
22. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus.
Imai J; Ieiri I; Mamiya K; Miyahara S; Furuumi H; Nanba E; Yamane M; Fukumaki Y; Ninomiya H; Tashiro N; Otsubo K; Higuchi S
Pharmacogenetics; 2000 Feb; 10(1):85-9. PubMed ID: 10739176
[No Abstract] [Full Text] [Related]
23. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].
Huang Y; Yang JF; Qi XL; Wang YQ; Wang WZ; Chen B
Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1686-9. PubMed ID: 15569425
[TBL] [Abstract][Full Text] [Related]
24. The role of CYP2C9 polymorphisms in phenytoin-related cerebellar atrophy.
Twardowschy CA; Werneck LC; Scola RH; Borgio JG; De Paola L; Silvado C
Seizure; 2013 Apr; 22(3):194-7. PubMed ID: 23298603
[TBL] [Abstract][Full Text] [Related]
25. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity.
Depondt C; Godard P; Espel RS; Da Cruz AL; Lienard P; Pandolfo M
Eur J Neurol; 2011 Sep; 18(9):1159-64. PubMed ID: 21338443
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine.
López M; Dorado P; Monroy N; Alonso ME; Jung-Cook H; Machín E; Peñas-Lledó E; Llerena A
Drug Metabol Drug Interact; 2011; 26(1):5-12. PubMed ID: 21557672
[TBL] [Abstract][Full Text] [Related]
27. Phenytoin intoxication induced by fluvoxamine.
Mamiya K; Kojima K; Yukawa E; Higuchi S; Ieiri I; Ninomiya H; Tashiro N
Ther Drug Monit; 2001 Feb; 23(1):75-7. PubMed ID: 11206048
[TBL] [Abstract][Full Text] [Related]
28. Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy.
Chaudhary N; Kabra M; Gulati S; Gupta YK; Pandey RM; Bhatia BD
BMC Pediatr; 2016 May; 16():66. PubMed ID: 27179628
[TBL] [Abstract][Full Text] [Related]
29. The association between CYP 2C9 polymorphism and bone health.
Phabphal K; Geater A; Limapichat K; Sathirapanya P; Setthawatcharawanich S; Leelawattana R
Seizure; 2013 Nov; 22(9):766-71. PubMed ID: 23849849
[TBL] [Abstract][Full Text] [Related]
30. Comparative efficacy of antiepileptic drugs for patients with generalized epileptic seizures: systematic review and network meta-analyses.
Campos MSA; Ayres LR; Morelo MRS; Carizio FAM; Pereira LRL
Int J Clin Pharm; 2018 Jun; 40(3):589-598. PubMed ID: 29744790
[TBL] [Abstract][Full Text] [Related]
31. [Anticonvulsive pharmacotherapy may aggravate epilepsy course].
Zenkov LR
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(10):52-4. PubMed ID: 16281381
[No Abstract] [Full Text] [Related]
32. Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children.
Suvichapanich S; Jittikoon J; Wichukchinda N; Kamchaisatian W; Visudtibhan A; Benjapopitak S; Nakornchai S; Manuyakorn W; Mahasirimongkol S
J Hum Genet; 2015 Aug; 60(8):413-7. PubMed ID: 25994870
[TBL] [Abstract][Full Text] [Related]
33. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
Hashimoto Y; Otsuki Y; Odani A; Takano M; Hattori H; Furusho K; Iui K
Biol Pharm Bull; 1996 Aug; 19(8):1103-5. PubMed ID: 8874828
[TBL] [Abstract][Full Text] [Related]
34. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy.
de Silva M; MacArdle B; McGowan M; Hughes E; Stewart J; Neville BG; Johnson AL; Reynolds EH
Lancet; 1996 Mar; 347(9003):709-13. PubMed ID: 8601999
[TBL] [Abstract][Full Text] [Related]
35. [Oligospermia improved by switching an anticonvulsant from phenytoin to valproate].
Niwa K; Kitagawa Y; Yoshii F; Shinohara Y
Rinsho Shinkeigaku; 1996 Mar; 36(3):492-4. PubMed ID: 8741357
[TBL] [Abstract][Full Text] [Related]
36. Use of multi-dose activated charcoal in phenytoin toxicity secondary to genetic polymorphism.
Chan BS; Sellors K; Chiew AL; Buckley NA
Clin Toxicol (Phila); 2015 Feb; 53(2):131-3. PubMed ID: 25597548
[TBL] [Abstract][Full Text] [Related]
37. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial.
Heller AJ; Chesterman P; Elwes RD; Crawford P; Chadwick D; Johnson AL; Reynolds EH
J Neurol Neurosurg Psychiatry; 1995 Jan; 58(1):44-50. PubMed ID: 7823066
[TBL] [Abstract][Full Text] [Related]
38. Management of generalised convulsive status epilepticus (SE): A prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam--Pilot study.
Mundlamuri RC; Sinha S; Subbakrishna DK; Prathyusha PV; Nagappa M; Bindu PS; Taly AB; Umamaheswara Rao GS; Satishchandra P
Epilepsy Res; 2015 Aug; 114():52-8. PubMed ID: 26088885
[TBL] [Abstract][Full Text] [Related]
39. Association of CYP2D6 100 C > T and 2850 C > T polymorphisms with generalized tonic clonic seizures among Indians.
Soundararajan CC; Adhin A; Tripathi M; Prasad HK; Jain S; Vivekanandhan S
J Neural Transm (Vienna); 2006 Dec; 113(12):1873-6. PubMed ID: 16835697
[TBL] [Abstract][Full Text] [Related]
40. Impact of MTHFR (C677T) gene polymorphism on antiepileptic drug monotherapy in North Indian epileptic population.
Munisamy M; Al-Gahtany M; Tripathi M; Subbiah V
Ann Saudi Med; 2015; 35(1):51-7. PubMed ID: 26142939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
